Charon R Ganellin

Title: Charon R Ganellin: Innovator in Histamine Agonist Research

Introduction

Charon R Ganellin is a notable inventor recognized for his contributions to the field of pharmacology, particularly in the development of histamine agonists. His work has significant implications for various therapeutic applications, including treatments for sleep disorders and respiratory conditions.

Latest Patents

Ganellin holds a patent for a method of inducing a histamine agonist action on H₂ receptors. The invention claims drugs that are active as agonists of the histamine H₃ receptor, including O-[2-(4(5-imidazolyl)-ethyl] isothiourea, 4-(4(5)-imidazolyl) butyramidine, and S-[2-(4(5)-imidazolyl)-ethyl] isourea, along with their N-methyl derivatives. These compounds are useful for preparing drugs intended for use as hypnotics, sleep inducers, tranquilizers, sedatives, anxiolytics, anti-asthmatics, and anti-inflammatory agents, particularly for the bronchi, skin, or eyes, as well as for treating gastric ulcers.

Career Highlights

Throughout his career, Ganellin has worked with prominent organizations, including Société Civile Bioprojet and Institut National de la Santé et de la Recherche Médicale. His research has contributed to advancements in drug development and therapeutic strategies.

Collaborations

Ganellin has collaborated with esteemed colleagues such as Jean Charles Schwartz and Monique Garbarg, enhancing the impact of his research through shared expertise and innovation.

Conclusion

Charon R Ganellin's work in histamine agonist research has paved the way for new therapeutic options in medicine. His contributions continue to influence the field and improve patient care.